Bioxytran BIXT
OTC BIXT
$0.02 +0.00 (+0.00%)
At close: Sep 25, 2026 · 4:00 PM EDT

Bioxytran (BIXT) Current Deferred Revenue (2017)

Updated

Bioxytran (BIXT) reported Current Deferred Revenue of $4,800 for Q4 2017.

Analysis

Bioxytran (BIXT) Current Deferred Revenue (2017) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn
10 Bioxytran 2.29 Mn 1.13 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2017 4,800.00
API Access

Bioxytran Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=BIXT&period=max&api_key=YOUR_API_KEY